IXAMIB 4mg (Ixazomib Capsule) 4mg

IXAMIB 4mg (Ixazomib) is an oral proteasome inhibitor used for multiple myeloma treatment. This 4mg capsule supports systemic therapy with convenient once-weekly dosing. Suitable for patients requiring proteasome inhibition as part of their regimen. Always follow healthcare provider guidance when using this medication.

Strength

4mg

Manufacturer / TM Owner

Azista Bhutan Healthcare Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

IXAMIB 4mg is used to treat multiple myeloma, a type of blood cancer affecting plasma cells. It works by blocking proteasomes, proteins that help cancer cells break down waste, causing cell stress. Often prescribed alongside other medications for systemic therapy. Commonly used for relapsed or refractory multiple myeloma cases.

Side Effects

IXAMIB 4mg may cause gastrointestinal effects like nausea, diarrhea, or constipation. Some patients report fatigue, peripheral neuropathy, or reduced appetite. These effects vary by individual and are typically managed with supportive care. Regular monitoring helps track tolerance and adjust therapy as needed.

Precautions & Warnings

Store IXAMIB 4mg capsules at room temperature away from moisture and heat. Keep out of reach of children and pets. Avoid opening or crushing capsules to prevent exposure. Report any signs of infection, bleeding, or unusual symptoms to a healthcare provider promptly. Follow disposal guidelines for unused or expired medication.

Avoid Interactions

IXAMIB 4mg may interact with strong CYP3A inducers or inhibitors, altering its effectiveness. Avoid grapefruit products, as they can affect drug metabolism. Some medications, including certain antivirals or antifungals, may increase ixazomib levels. Discuss all current medications with a healthcare provider before starting ixazomib therapy.

References

Frequently Asked Questions

IXAMIB 4mg is used to treat multiple myeloma, a cancer affecting plasma cells in the bone marrow.

Take IXAMIB 4mg capsules once weekly on an empty stomach, at least one hour before or two hours after food.

Common side effects include nausea, diarrhea, fatigue, and peripheral neuropathy.

Consult a healthcare provider before combining IXAMIB 4mg with other drugs, as interactions may occur.

IXAMIB 4mg may harm an unborn baby; discuss risks and contraception with a healthcare provider before use.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.